Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) and Subjects With Diabetic Macular Edema (DME)

NCT03835884 is registered in ClinicalTrials.gov with Aerie Pharmaceuticals as lead sponsor.

NCT NCT03835884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03835884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) and Subjects With Diabetic Macular Edema (DME)
Lead sponsor
Aerie Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
June 24, 2019
Completion date
May 12, 2022
Enrollment
18 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema, neovascular age-related macular degeneration